Review




Structured Review

Valiant Co Ltd dimethyl sulfoxide
Dimethyl Sulfoxide, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 97/100, based on 1012 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dmso/Dimethyl+sulfoxide/pmc13130641-76-0-3
Average 97 stars, based on 1012 article reviews
dimethyl sulfoxide - by Bioz Stars, 2026-11
97/100 stars

Images

Related Articles

Saline:

Article Title: Schisandrin B identified by CMC ameliorates PGN-induced immune colitis and DSS-triggered ulcerative colitis by targeting TLR2 and blocking TLR2 heterodimerization
Article Snippet: .. Different concentrations of SchB 260 were prepared in running buffer (1.05× phosphate-buffered saline with Surfactant P20 (PBS-P+), 261 containing 5% dimethyl sulfoxide (DMSO) (02196055, MP Biomedicals, Solon, OH, USA)). .. Binding 262 evaluation followed the Biocore T200 experimental guidelines.

Indirect Immunoperoxidase Assay:

Article Title: Indole-3-Propionic Acid Disrupts Glycolytic Adaptation and Promotes Oxidative Stress-Associated Injury in Oral Squamous Cell Carcinoma.
Article Snippet: .. IPA (Cat. No. V22550, InvivoChem, North Aurora, IL, USA) was first dissolved in dimethyl sulfoxide (DMSO, MP Biomedicals, Ohio, USA) to prepare a concentrated stock solution (500 mM). ..

MTT Assay:

Article Title: Three New Norsesquiterpenoids from the Twigs and Leaves of Nanhaia speciosa
Article Snippet: Cisplatin (CDDP) was purchased from MedChemExpress (MCE). .. MTT was obtained from TaoSu Biotech Co., Ltd. (Shanghai, China), and dimethyl sulfoxide (DMSO) was purchased from MP Biomedicals. ..

Modification:

Article Title: Liposome-incorporated multifunctional hydrogel for localized and controlled release of drug for the treatment of chronic diabetic wounds
Article Snippet: Diabetic wounds (DW) remain a significant healthcare challenge due to persistent infection, oxidative stress, and impaired healing, leading to high costs, amputations, and significant morbidity.. This underscores an urgent need for the development of a cost-effective drug delivery platform that can overcome these challenges.. Therefore, this study reports the development of a multifunctional hybrid hydrogel incorporating stimuli-responsive liposomes prepared via a microfluidic method for localized and controlled wound therapy.



Similar Products

99
MedChemExpress sterile dmso
Sterile Dmso, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dmso/OF-1/pm43015474-725-9-4
Average 99 stars, based on 1 article reviews
sterile dmso - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
Beijing Solarbio Science dimethyl sulfoxide
Dimethyl Sulfoxide, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dmso/DMSO/10__3892_slash_br__2026__2225-68-39-41
Average 99 stars, based on 1 article reviews
dimethyl sulfoxide - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
Beijing Solarbio Science dmso
Dmso, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dmso/DMSO/pm43003852-638-15-16
Average 99 stars, based on 1 article reviews
dmso - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

97
Valiant Co Ltd dimethyl sulfoxide dmso
Dimethyl Sulfoxide Dmso, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dmso/Dimethyl+sulfoxide/pmc13764921-150-11-17
Average 97 stars, based on 1 article reviews
dimethyl sulfoxide dmso - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

dmso  (Tocris)
96
Tocris dmso
a, RSV progeny release in focus forming units (FFU) from lHAEo-cells treated with 200pM loxoribine (Lox) at 0, 4, 8, or 24 hours post infection (hpi). b, RSV progeny release from HEK293T and lHAEo-cells transfected with either control plasmid or TLR7 expression plasmid. Above, a western blot shows RSV-G protein levels at different times following RSV infection in HEK 293T cells transfected with control plasmid or TLR7 expression plasmid. SOD1 protein expression is shown as a loading control, c, RSV progeny release from lHAEo-cells treated with scramble (Scr) or TLR7 siRNA. Above is a western blot showing RSV-G and TLR7 protein expression in lHAEo-cells treated with Scr or TLR7 siRNA, with SOD1 protein expression as a loading control, d, RSV progeny release from lHAEo-cells treated with 200pM Lox, 10pM of <t>U0126</t> (ERKi), or both at 4hpi. e, Western blot of phosphorylated BAD and elF4B in lHAEo-cells that were untreated (control) or treated with lOpM of U0126 (ERKi) and harvested at 0, 4, 6, 8, and 12 hours post RSV infection, f, A model of signalling mediator phosphorylation following RSV infection, g, RSV progeny release from MyD88, IRAK4, and TLR3 null fibroblast cells treated with 200pM Lox or DMSO at 4hpi. h, Progeny RSV and HP1V3 release from lHAEo-cells treated with MyD88 inhibitor TJ-M2010-5 (MyD88i) at 4hpi is shown on the right and left. In the centre, influenza A infected A549 cells in FFU were treated with MyD88i at 2hpi and quantified at 48hpi. i, Percentage of N 6 -methyladenosine (m 6 A) and 5-methylcytosine (m 5 C) base modifications averaged over 100bp bins over the RSV genome in RNA harvested from infected primary BECs treated with DMSO or U0126 (ERKi). Position of RSV genes from NS1 to L are depicted below the graphs. Area under the curve (AUC) from each treatment group quantifies the results from these graphs. Results are from one primary donor, j, RSV progeny release from lHAEo-cells treated at 4hpi with either TE control or 100nM, 500nM, and 1μM unmodified RNA or m6A modified RNA. a,b, d-h, and j are representative of 3 biological replicates, c is representative of 2 biological replicates.
Dmso, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dmso/U0126/bio_rxiv__64898__2026__11__03__764012-286-20-24
Average 96 stars, based on 1 article reviews
dmso - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

99
Beijing Solarbio Science dimethyl sulfoxide 217
a, RSV progeny release in focus forming units (FFU) from lHAEo-cells treated with 200pM loxoribine (Lox) at 0, 4, 8, or 24 hours post infection (hpi). b, RSV progeny release from HEK293T and lHAEo-cells transfected with either control plasmid or TLR7 expression plasmid. Above, a western blot shows RSV-G protein levels at different times following RSV infection in HEK 293T cells transfected with control plasmid or TLR7 expression plasmid. SOD1 protein expression is shown as a loading control, c, RSV progeny release from lHAEo-cells treated with scramble (Scr) or TLR7 siRNA. Above is a western blot showing RSV-G and TLR7 protein expression in lHAEo-cells treated with Scr or TLR7 siRNA, with SOD1 protein expression as a loading control, d, RSV progeny release from lHAEo-cells treated with 200pM Lox, 10pM of <t>U0126</t> (ERKi), or both at 4hpi. e, Western blot of phosphorylated BAD and elF4B in lHAEo-cells that were untreated (control) or treated with lOpM of U0126 (ERKi) and harvested at 0, 4, 6, 8, and 12 hours post RSV infection, f, A model of signalling mediator phosphorylation following RSV infection, g, RSV progeny release from MyD88, IRAK4, and TLR3 null fibroblast cells treated with 200pM Lox or DMSO at 4hpi. h, Progeny RSV and HP1V3 release from lHAEo-cells treated with MyD88 inhibitor TJ-M2010-5 (MyD88i) at 4hpi is shown on the right and left. In the centre, influenza A infected A549 cells in FFU were treated with MyD88i at 2hpi and quantified at 48hpi. i, Percentage of N 6 -methyladenosine (m 6 A) and 5-methylcytosine (m 5 C) base modifications averaged over 100bp bins over the RSV genome in RNA harvested from infected primary BECs treated with DMSO or U0126 (ERKi). Position of RSV genes from NS1 to L are depicted below the graphs. Area under the curve (AUC) from each treatment group quantifies the results from these graphs. Results are from one primary donor, j, RSV progeny release from lHAEo-cells treated at 4hpi with either TE control or 100nM, 500nM, and 1μM unmodified RNA or m6A modified RNA. a,b, d-h, and j are representative of 3 biological replicates, c is representative of 2 biological replicates.
Dimethyl Sulfoxide 217, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dmso/DMSO/pm42977136-108-18-22
Average 99 stars, based on 1 article reviews
dimethyl sulfoxide 217 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

98
MedChemExpress dmso
a, RSV progeny release in focus forming units (FFU) from lHAEo-cells treated with 200pM loxoribine (Lox) at 0, 4, 8, or 24 hours post infection (hpi). b, RSV progeny release from HEK293T and lHAEo-cells transfected with either control plasmid or TLR7 expression plasmid. Above, a western blot shows RSV-G protein levels at different times following RSV infection in HEK 293T cells transfected with control plasmid or TLR7 expression plasmid. SOD1 protein expression is shown as a loading control, c, RSV progeny release from lHAEo-cells treated with scramble (Scr) or TLR7 siRNA. Above is a western blot showing RSV-G and TLR7 protein expression in lHAEo-cells treated with Scr or TLR7 siRNA, with SOD1 protein expression as a loading control, d, RSV progeny release from lHAEo-cells treated with 200pM Lox, 10pM of <t>U0126</t> (ERKi), or both at 4hpi. e, Western blot of phosphorylated BAD and elF4B in lHAEo-cells that were untreated (control) or treated with lOpM of U0126 (ERKi) and harvested at 0, 4, 6, 8, and 12 hours post RSV infection, f, A model of signalling mediator phosphorylation following RSV infection, g, RSV progeny release from MyD88, IRAK4, and TLR3 null fibroblast cells treated with 200pM Lox or DMSO at 4hpi. h, Progeny RSV and HP1V3 release from lHAEo-cells treated with MyD88 inhibitor TJ-M2010-5 (MyD88i) at 4hpi is shown on the right and left. In the centre, influenza A infected A549 cells in FFU were treated with MyD88i at 2hpi and quantified at 48hpi. i, Percentage of N 6 -methyladenosine (m 6 A) and 5-methylcytosine (m 5 C) base modifications averaged over 100bp bins over the RSV genome in RNA harvested from infected primary BECs treated with DMSO or U0126 (ERKi). Position of RSV genes from NS1 to L are depicted below the graphs. Area under the curve (AUC) from each treatment group quantifies the results from these graphs. Results are from one primary donor, j, RSV progeny release from lHAEo-cells treated at 4hpi with either TE control or 100nM, 500nM, and 1μM unmodified RNA or m6A modified RNA. a,b, d-h, and j are representative of 3 biological replicates, c is representative of 2 biological replicates.
Dmso, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dmso/Dimethyl+sulfoxide%2C+meets+analytical+specification+of+Ch%2EP/pm42977749-69-39-41
Average 98 stars, based on 1 article reviews
dmso - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

99
Beijing Solarbio Science dimethyl sulfoxide dmso
a, RSV progeny release in focus forming units (FFU) from lHAEo-cells treated with 200pM loxoribine (Lox) at 0, 4, 8, or 24 hours post infection (hpi). b, RSV progeny release from HEK293T and lHAEo-cells transfected with either control plasmid or TLR7 expression plasmid. Above, a western blot shows RSV-G protein levels at different times following RSV infection in HEK 293T cells transfected with control plasmid or TLR7 expression plasmid. SOD1 protein expression is shown as a loading control, c, RSV progeny release from lHAEo-cells treated with scramble (Scr) or TLR7 siRNA. Above is a western blot showing RSV-G and TLR7 protein expression in lHAEo-cells treated with Scr or TLR7 siRNA, with SOD1 protein expression as a loading control, d, RSV progeny release from lHAEo-cells treated with 200pM Lox, 10pM of <t>U0126</t> (ERKi), or both at 4hpi. e, Western blot of phosphorylated BAD and elF4B in lHAEo-cells that were untreated (control) or treated with lOpM of U0126 (ERKi) and harvested at 0, 4, 6, 8, and 12 hours post RSV infection, f, A model of signalling mediator phosphorylation following RSV infection, g, RSV progeny release from MyD88, IRAK4, and TLR3 null fibroblast cells treated with 200pM Lox or DMSO at 4hpi. h, Progeny RSV and HP1V3 release from lHAEo-cells treated with MyD88 inhibitor TJ-M2010-5 (MyD88i) at 4hpi is shown on the right and left. In the centre, influenza A infected A549 cells in FFU were treated with MyD88i at 2hpi and quantified at 48hpi. i, Percentage of N 6 -methyladenosine (m 6 A) and 5-methylcytosine (m 5 C) base modifications averaged over 100bp bins over the RSV genome in RNA harvested from infected primary BECs treated with DMSO or U0126 (ERKi). Position of RSV genes from NS1 to L are depicted below the graphs. Area under the curve (AUC) from each treatment group quantifies the results from these graphs. Results are from one primary donor, j, RSV progeny release from lHAEo-cells treated at 4hpi with either TE control or 100nM, 500nM, and 1μM unmodified RNA or m6A modified RNA. a,b, d-h, and j are representative of 3 biological replicates, c is representative of 2 biological replicates.
Dimethyl Sulfoxide Dmso, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dmso/DMSO/bio_rxiv__64898__2026__11__01__763500-40-0-6
Average 99 stars, based on 1 article reviews
dimethyl sulfoxide dmso - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


a, RSV progeny release in focus forming units (FFU) from lHAEo-cells treated with 200pM loxoribine (Lox) at 0, 4, 8, or 24 hours post infection (hpi). b, RSV progeny release from HEK293T and lHAEo-cells transfected with either control plasmid or TLR7 expression plasmid. Above, a western blot shows RSV-G protein levels at different times following RSV infection in HEK 293T cells transfected with control plasmid or TLR7 expression plasmid. SOD1 protein expression is shown as a loading control, c, RSV progeny release from lHAEo-cells treated with scramble (Scr) or TLR7 siRNA. Above is a western blot showing RSV-G and TLR7 protein expression in lHAEo-cells treated with Scr or TLR7 siRNA, with SOD1 protein expression as a loading control, d, RSV progeny release from lHAEo-cells treated with 200pM Lox, 10pM of U0126 (ERKi), or both at 4hpi. e, Western blot of phosphorylated BAD and elF4B in lHAEo-cells that were untreated (control) or treated with lOpM of U0126 (ERKi) and harvested at 0, 4, 6, 8, and 12 hours post RSV infection, f, A model of signalling mediator phosphorylation following RSV infection, g, RSV progeny release from MyD88, IRAK4, and TLR3 null fibroblast cells treated with 200pM Lox or DMSO at 4hpi. h, Progeny RSV and HP1V3 release from lHAEo-cells treated with MyD88 inhibitor TJ-M2010-5 (MyD88i) at 4hpi is shown on the right and left. In the centre, influenza A infected A549 cells in FFU were treated with MyD88i at 2hpi and quantified at 48hpi. i, Percentage of N 6 -methyladenosine (m 6 A) and 5-methylcytosine (m 5 C) base modifications averaged over 100bp bins over the RSV genome in RNA harvested from infected primary BECs treated with DMSO or U0126 (ERKi). Position of RSV genes from NS1 to L are depicted below the graphs. Area under the curve (AUC) from each treatment group quantifies the results from these graphs. Results are from one primary donor, j, RSV progeny release from lHAEo-cells treated at 4hpi with either TE control or 100nM, 500nM, and 1μM unmodified RNA or m6A modified RNA. a,b, d-h, and j are representative of 3 biological replicates, c is representative of 2 biological replicates.

Journal: bioRxiv

Article Title: Lung Epithelial TLR7 is a Factor in Viral Replication and Pathogenesis

doi: 10.64898/2026.11.03.764012

Figure Lengend Snippet: a, RSV progeny release in focus forming units (FFU) from lHAEo-cells treated with 200pM loxoribine (Lox) at 0, 4, 8, or 24 hours post infection (hpi). b, RSV progeny release from HEK293T and lHAEo-cells transfected with either control plasmid or TLR7 expression plasmid. Above, a western blot shows RSV-G protein levels at different times following RSV infection in HEK 293T cells transfected with control plasmid or TLR7 expression plasmid. SOD1 protein expression is shown as a loading control, c, RSV progeny release from lHAEo-cells treated with scramble (Scr) or TLR7 siRNA. Above is a western blot showing RSV-G and TLR7 protein expression in lHAEo-cells treated with Scr or TLR7 siRNA, with SOD1 protein expression as a loading control, d, RSV progeny release from lHAEo-cells treated with 200pM Lox, 10pM of U0126 (ERKi), or both at 4hpi. e, Western blot of phosphorylated BAD and elF4B in lHAEo-cells that were untreated (control) or treated with lOpM of U0126 (ERKi) and harvested at 0, 4, 6, 8, and 12 hours post RSV infection, f, A model of signalling mediator phosphorylation following RSV infection, g, RSV progeny release from MyD88, IRAK4, and TLR3 null fibroblast cells treated with 200pM Lox or DMSO at 4hpi. h, Progeny RSV and HP1V3 release from lHAEo-cells treated with MyD88 inhibitor TJ-M2010-5 (MyD88i) at 4hpi is shown on the right and left. In the centre, influenza A infected A549 cells in FFU were treated with MyD88i at 2hpi and quantified at 48hpi. i, Percentage of N 6 -methyladenosine (m 6 A) and 5-methylcytosine (m 5 C) base modifications averaged over 100bp bins over the RSV genome in RNA harvested from infected primary BECs treated with DMSO or U0126 (ERKi). Position of RSV genes from NS1 to L are depicted below the graphs. Area under the curve (AUC) from each treatment group quantifies the results from these graphs. Results are from one primary donor, j, RSV progeny release from lHAEo-cells treated at 4hpi with either TE control or 100nM, 500nM, and 1μM unmodified RNA or m6A modified RNA. a,b, d-h, and j are representative of 3 biological replicates, c is representative of 2 biological replicates.

Article Snippet: Primary human BECs were seeded in 6 well plates, infected with RSV at an MOI of 0.5, and treated with DMSO or 10μM U0126 (Tocris, 1144/5) at 4 hours post infection.

Techniques: Infection, Transfection, Control, Plasmid Preparation, Expressing, Western Blot, Phospho-proteomics, Modification

a, RSV progeny release from lHAEo-cells following U0126 and SCH772984 treatment at 4hpi. b, A schematic of common signalling at different points in the RSV life cycle, c, ERK phosphorylation following RSV infection in lHAEo-cells is shown by western blot, d, p90RSK phosphorylation at S380 in lHAEo-cells that were untreated (top) or treated with U0126 (ERKi, bottom) and infected with RSV is shown by western blot. Densitometry relative to loading controls is shown below each band, e, ERK and p90RSK phosphorylation in lHAEo-cells infected with HPIV3 are shown by western blot. Densitometry relative to loading controls is shown below each band a, c, and d are representative of 3 independent experiments.

Journal: bioRxiv

Article Title: Lung Epithelial TLR7 is a Factor in Viral Replication and Pathogenesis

doi: 10.64898/2026.11.03.764012

Figure Lengend Snippet: a, RSV progeny release from lHAEo-cells following U0126 and SCH772984 treatment at 4hpi. b, A schematic of common signalling at different points in the RSV life cycle, c, ERK phosphorylation following RSV infection in lHAEo-cells is shown by western blot, d, p90RSK phosphorylation at S380 in lHAEo-cells that were untreated (top) or treated with U0126 (ERKi, bottom) and infected with RSV is shown by western blot. Densitometry relative to loading controls is shown below each band, e, ERK and p90RSK phosphorylation in lHAEo-cells infected with HPIV3 are shown by western blot. Densitometry relative to loading controls is shown below each band a, c, and d are representative of 3 independent experiments.

Article Snippet: Primary human BECs were seeded in 6 well plates, infected with RSV at an MOI of 0.5, and treated with DMSO or 10μM U0126 (Tocris, 1144/5) at 4 hours post infection.

Techniques: Phospho-proteomics, Infection, Western Blot